Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2016 | original article | Ausgabe 1-2/2016

Wiener klinische Wochenschrift 1-2/2016

Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 1-2/2016
Autoren:
MD Efnan Algin, Ahmet Ozet, Ozge Gumusay, Guldal Yilmaz, Suleyman Buyukberber, Ugur Coskun, Meltem Baykara, Bulent Cetin, Ramazan Yıldız, Mustafa Benekli

Summary

Background

In this retrospective study, we aimed to evaluate the clinicopathological characteristics of the patients presenting with liver metastases from unknown primary site besides survival rates, treatment outcomes, and prognostic factors.

Methods

In all, 68 patients followed-up at our center with adenocarcinoma of unknown primary (ACUP) metastatic to the liver between 2005 and 2013 were enrolled. All of the liver metastases were proven by liver biopsy and all yielded diagnosis of adenocarcinoma.

Results

Median age was 61 years (29–90) and most of the patients were male (male/female: 43/25). The liver was the only metastatic site in 2 (3 %) patients whilst 66 patients (97 %) had extrahepatic metastases. The most common extrahepatic metastatic sites were lymph nodes (89.7 %), lungs (32.4 %), bones (25 %), peritoneum (11.8 %), brain (4.4 %), and adrenal glands (2.9 %). Of all 68 patients, 39 (57.4 %) were treated with chemotherapy. Median overall survival (OS) was significantly higher in ACUP patients treated with chemotherapy [12.5 months (95 % CI 8.3–16.7) vs. 4 months (95 % CI 1.2–6.8), (p = 0.026), respectively]. In multivariate analysis, ECOG (Eastern Cooperative Oncology Group) performance status (p = 0.009), chemotherapy (p = 0.024), serum albumin (p = 0.012), and serum CA 19-9 level (p = 0.026) at initial diagnosis were identified as independent prognostic factors influencing survival for the patients with liver metastases from ACUP.

Conclusion

Patients with liver metastases from ACUP have poor prognosis and chemotherapy improves survival. Decreased serum albumin level, increased CA 19-9 level and poor performance status are independent poor prognostic factors.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2016

Wiener klinische Wochenschrift 1-2/2016 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen